-11.6%
ONDS vs GSK
+14.9%
-26.5%
-62.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -9.0% | +5.0% | -14.0% | -6.5% |
| 7D | -23.2% | +4.9% | -28.1% | -21.0% |
| 30D | -29.0% | +9.9% | -38.9% | -25.4% |
| 3M | -40.5% | +0.2% | -40.7% | -39.6% |
| 6M | -45.8% | +2.3% | -48.2% | -44.1% |
| YTD | -46.0% | +7.1% | -53.1% | -36.1% |
| 1Y | -11.6% | +13.1% | -24.7% | +8.0% |
| All | -11.6% | +14.9% | -26.5% | +8.0% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling